The Journal of Allergy and Clinical Immunology

Sublingual Immunotherapy May Result in Desensitization and Remission for Peanut-Allergic Children

Retrieved on:

tisdag, oktober 10, 2023

MILWAUKEE, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Peanut sublingual immunotherapy (SLIT) is safe for young children and results in a greater likelihood of desensitization and remission, according to new research published in The Journal of Allergy and Clinical Immunology (JACI), an official journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points:

60% of peanut-allergic children in the test group experience desensitization to peanut protein after sublingual immunotherapy according to research from JACI, an official journal of the AAAAI.
Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.
Conducted over a 36-month period, the double-blind, placebo-controlled study assessed the effectiveness of peanut sublingual immunotherapy (SLIT) on 50 children aged 1- to 4 years old.
Upon assessment, 60% of children in the study were found to experience desensitization to peanut protein, and 48% experienced remission three months after therapy.

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

Retrieved on:

tisdag, oktober 3, 2023

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.

Key Points:

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.
The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.
For repeat doses of neffy, mean maximum changes in PD responses for both blood pressure and heart rate were statistically greater than repeat doses of EpiPen.
In addition, the PK profile for a second dose of neffy was approximately dose-proportional, unlike EpiPen, where the second dose delivered less incremental epinephrine exposure than the first dose.

DiCello Levitt: Pharmaceutical Companies Violated Consumer Protection Laws, Committed Fraud by Selling Medicine Containing Ineffective Nasal Decongestant, According to New Lawsuit

Retrieved on:

torsdag, september 14, 2023

The complaint is among the first to be filed following a Food & Drug Administration advisory panel’s unanimous finding that the ingredient, phenylephrine, is ineffective in oral medication.

Key Points:

The complaint is among the first to be filed following a Food & Drug Administration advisory panel’s unanimous finding that the ingredient, phenylephrine, is ineffective in oral medication.
In the last year alone, nearly $1.8 billion in sales of such phenylephrine-containing purported decongestants were made in the United States across 250 products.
In a 2006 report published in the Journal of Allergy and Clinical Immunology, researchers found that “Phenylephrine…is unlikely to provide relief of nasal congestion.
A copy of the complaint is available upon request, and attorneys from DiCello Levitt are available for media interviews.

Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma

Retrieved on:

torsdag, augusti 3, 2023

Areteia Therapeutics, Inc. (“Areteia”) today announced that results from the Phase II EXHALE-1 study of dexpramipexole have been published online in the Journal of Allergy and Clinical Immunology (JACI).

Key Points:

Areteia Therapeutics, Inc. (“Areteia”) today announced that results from the Phase II EXHALE-1 study of dexpramipexole have been published online in the Journal of Allergy and Clinical Immunology (JACI).
The study sought to evaluate the safety and efficacy of dexpramipexole in lowering blood and airway eosinophilia in subjects with eosinophilic asthma.
Dexpramipexole reduced the exploratory end point of nasal eosinophil peroxidase, a biomarker of tissue eosinophilic inflammation, in both the 150-mg BID and the 75-mg BID groups.
Clinically meaningful improvements in lung function as measured by forced expiratory volume (FEV1) were observed starting at week 4.

Asthma Patients Undergoing Regular High-intensity Exercise May be Able to Reduce Daily Inhaled Corticosteroid Dosage

Retrieved on:

onsdag, maj 31, 2023

MILWAUKEE, May 31, 2023 /PRNewswire-PRWeb/ -- Supervised high-intensity interval training could reduce the need for inhaled corticosteroids (ICS) in asthma patients who had not previously undergone this type of exercise, supporting exercise as a nonpharmacological component of asthma management. The finding comes from a new study published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points:

Patients in the exercise group were able to reduce doses without compromising their asthma control according to research from JACI: In Practice, an official journal of the AAAAI.
MILWAUKEE, May 31, 2023 /PRNewswire-PRWeb/ -- Supervised high-intensity interval training could reduce the need for inhaled corticosteroids (ICS) in asthma patients who had not previously undergone this type of exercise, supporting exercise as a nonpharmacological component of asthma management.
The control group maintained their regular lifestyle while the exercise group underwent six months of ongoing supervised high-intensity exercise three times a week.
April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
SOURCE The American Academy of Allergy, Asthma & Immunology

Women's Exposure to Domestic Violence Associated with Risk of Developing Atopic Diseases

Retrieved on:

fredag, maj 5, 2023

MILWAUKEE, May 5, 2023 /PRNewswire-PRWeb/ -- Being a woman exposed to domestic violence and abuse is positively associated with the development of atopic disease, with the association strongest for asthma development, according to research published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points:

"After adjusting for possible cofounders, our results show women with a recorded exposure to domestic violence and abuse had a 52% increased risk of developing atopic diseases," said Dr Joht Singh Chandan, PhD, corresponding author of the study.
"We set out to deepen our understanding of the health impacts of domestic violence so evidence-based public health policies can be further developed to address not only domestic violence, but secondary effects like the development of atopic diseases," Dr. Chandan said.
A total of 13,852 women were identified as being exposed to domestic violence and were matched to 49,036 similar women without a reported exposure.
If you or someone you know is experiencing domestic violence, visit the National Domestic Violence Hotline website or contact their hotline at 1-800-799-7233 for assistance.

Molekule to Preview Pre-Clinical Allergen Trial Results at Upcoming AAAAI Annual Meeting

Retrieved on:

torsdag, februari 23, 2023

Allergist, Development, Research and development, Molekule, Allergen, American Academy of Allergy, Asthma, and Immunology, Annual general meeting, PALM, Journal, Patient, AAAAI, Inflammation, The Journal of Allergy and Clinical Immunology, Asthma, PECO, American Academy, Pharmaceutical industry, Research, Allergy

PALM BEACH GARDENS, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Molekule Group, Inc (Nasdaq: MKUL), a leader in reinventing air purification, will showcase new research findings at the 2023 American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting. Gathering researchers and experts in allergies, asthma, and immunology, the AAAAI Annual Meeting will take place February 24-27 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Molekule’s Vice President of Research and Development, Jaspreet Dhau, will share the findings of a recently completed pre-clinical trial study at the event and highlight the benefits of Molekule’s technology for patients with allergies and asthma.

Key Points:

Gathering researchers and experts in allergies, asthma, and immunology, the AAAAI Annual Meeting will take place February 24-27 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
“Indoor air quality is of the utmost importance to patients worldwide,” stated Gregory Bensch, M.D., President of Allergy, Asthma, and Immunology Medical Group.
“Molekule’s recent study demonstrates that even undetectable amounts of allergens can precipitate type 2 inflammation that drives rhinitis and asthma in many patients.
At the AAAAI Annual Meeting, Molekule will be presenting the following research:
Who: Jaspreet Dhau, Vice President of Research and Development, Molekule

Unnecessary Food Allergy Panel Testing Can Create Burden for Patients

Retrieved on:

tisdag, februari 21, 2023

MILWAUKEE, Feb. 21, 2023 /PRNewswire-PRWeb/ -- Inappropriate food IgE testing continues to be overutilized in patients exhibiting chronic, nonspecific symptoms., according to new research being presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI). "This leads to patients experiencing unnecessary anxiety, and often prompts patients to eliminate foods from their diets that they can safely consume," said Jenika Ferretti-Gallon, MD, primary author of the study.

Key Points:

Indiscriminate food allergy screenings can lead to increased anxiety and food avoidance in patients, according to research to be presented at the 2023 AAAAI Annual Meeting.
Researchers completed a retrospective chart review of 236 pediatric patients with food allergy testing at a single institution.
The EMR was implemented in February 2021 to provide a hard-stop alert when food allergy panels were ordered and instead recommend targeted testing.
April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
SOURCE The American Academy of Allergy, Asthma & Immunology

The Pediatric Asthma Risk Score Can Help Predict Asthma Development in Children

Retrieved on:

måndag, februari 20, 2023

Journal, AUC, Meta-analysis, Allergist, AAAAI, API, Patient, Asthma, The Journal of Allergy and Clinical Immunology, PARS, Research, Risk, American Academy, American Academy of Allergy, Asthma, and Immunology, Doctor of Philosophy, Pharmaceutical industry, Immunology, Allergy

MILWAUKEE, Feb. 20, 2023 /PRNewswire-PRWeb/ -- Researchers have confirmed the effectiveness of the Pediatric Asthma Risk Score (PARS) after validating its use with diverse cohorts from across the United States. The results are being presented in full during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points:

MILWAUKEE, Feb. 20, 2023 /PRNewswire-PRWeb/ -- Researchers have confirmed the effectiveness of the Pediatric Asthma Risk Score (PARS) after validating its use with diverse cohorts from across the United States.
"PARS is a continuous score that was developed to predict early-life asthma.
"This validates our previous results and could lead to PARS ultimately becoming a new quantitative gold standard in pediatric asthma risk prediction."
April Presnell, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected]
SOURCE The American Academy of Allergy, Asthma & Immunology

Researchers Discover Nasal miRNAs Present During Severe Bronchiolitis Associated with Risks of Asthma Development in Children

Retrieved on:

fredag, februari 17, 2023

MILWAUKEE, Feb. 17, 2023 /PRNewswire-PRWeb/ -- Bronchiolitis requiring hospitalization is associated with childhood asthma, and now researchers have identified nasal miRNAs present during severe bronchiolitis are linked to the risk of asthma development. Researchers will present their findings during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points:

MILWAUKEE, Feb. 17, 2023 /PRNewswire-PRWeb/ -- Bronchiolitis requiring hospitalization is associated with childhood asthma, and now researchers have identified nasal miRNAs present during severe bronchiolitis are linked to the risk of asthma development.
Researchers will present their findings during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Researchers decided to examine the longitudinal relationship between the risk of asthma development and nasal airway microRNAs (miRNAs) during severe bronchiolitis.
"We found a complex interplay between nasal miRNA, virus, asthma risk factors, and their longitudinal relationship with asthma development," Dr. Zhu said.